Literature DB >> 862653

Cerebrospinal fluid amine metabolites after combined amitriptyline-triiodothyronine treatment of depressed women.

C M Banki.   

Abstract

Levels of 5-hydroxyindoleacetic acid and homovanillic acid were measured in cerebrospinal fluid from 33 depressed women with no clinical response to amitriptyline, before and after combination treatment with triiodothyronine. Although the latter showed significant clinical improvement, changes in CSF amine metabolites did not differ significantly from a control group of 16 therapy-resistant depressed women receiving higher doses of amitriptyline. Possible explanations for the mechanism of action of triiodothyronine are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 862653     DOI: 10.1007/bf00607682

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  29 in total

1.  [The use of triiodothyronine in the treatment of depression].

Authors:  C Bánki
Journal:  Orv Hetil       Date:  1975-10-26       Impact factor: 0.540

2.  INHIBITION OF UPTAKE OF TRITIATED-NORADRENALINE IN THE INTACT RAT BRAIN BY IMIPRAMINE AND STRUCTURALLY RELATED COMPOUNDS.

Authors:  J GLOWINSKI; J AXELROD
Journal:  Nature       Date:  1964-12-26       Impact factor: 49.962

3.  Urinary adenosine 3',5'-monophosphate excretion in affective disorders.

Authors:  M I Paul; B R Ditzion; G L Pauk; D S Janowsky
Journal:  Am J Psychiatry       Date:  1970-04       Impact factor: 18.112

4.  Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressive states.

Authors:  C Ogura; T Okuma; Y Uchida; S Imai; H Yogi
Journal:  Folia Psychiatr Neurol Jpn       Date:  1974

5.  Cyclic A.M.P. in depression and mania.

Authors:  E N Ramsden
Journal:  Lancet       Date:  1970-07-11       Impact factor: 79.321

6.  3',5' cyclic adenosine monophosphate in depression and mania.

Authors:  Y H Abdulla; K Hamadah
Journal:  Lancet       Date:  1970-02-21       Impact factor: 79.321

7.  Thyroid-hormone enhancement of imipramine in nonretarded depressions.

Authors:  I C Wilson; A J Prange; T K McClane; A M Rabon; M A Lipton
Journal:  N Engl J Med       Date:  1970-05-07       Impact factor: 91.245

8.  5-Hydroxyindolacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis.

Authors:  R Sjöström; B E Roos
Journal:  Eur J Clin Pharmacol       Date:  1972-06       Impact factor: 2.953

9.  Abnormalities of indoleamines in affective disorders.

Authors:  A Coppen; A J Prange; P C Whybrow; R Noguera
Journal:  Arch Gen Psychiatry       Date:  1972-05

10.  [Clinical and neuro-endocrinological study of trh in melancholia].

Authors:  M Breulet; S Bourdouxhe; M Parent; J J Legros; J Bobon
Journal:  Acta Psychiatr Belg       Date:  1974-05
View more
  4 in total

Review 1.  Hormone treatment of depression.

Authors:  Russell T Joffe
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

2.  Alterations of cerebrospinal fluid 5-hydroxyindoleacetic acid, and total blood serotonin content during clozapine treatment.

Authors:  C M Banki
Journal:  Psychopharmacology (Berl)       Date:  1978-03-01       Impact factor: 4.530

Review 3.  Liothyronine for Depression: A Review and Guidance for Safety Monitoring.

Authors:  Katie T B Touma; Allysa M Zoucha; Jonathan R Scarff
Journal:  Innov Clin Neurosci       Date:  2017-04-01

4.  Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?

Authors:  Nefize Yalin; Allan H Young
Journal:  Neuropsychiatr Dis Treat       Date:  2020-06-09       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.